Hims & Hers Health is trading 4% down at €25.64 after its August 10, 2026 second-quarter report showed a $0.37 GAAP loss per share, versus a $0.05 estimate.
- Revenue reached $753.2 million, but the branded weight-loss drug transition increased costs and pressured margins.
- The company raised full-year revenue guidance to $3.2 billion, yet investors focused on the earnings miss and near-term profitability concerns.